Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Nicotinamide Riboside + Resveratrol	33
Overall Study	STARTED	Nicotinamide Riboside + Placebo	28
Overall Study	STARTED	Placebo + Placebo	29
Overall Study	3-month Follow-up	Nicotinamide Riboside + Resveratrol	30
Overall Study	3-month Follow-up	Nicotinamide Riboside + Placebo	26
Overall Study	3-month Follow-up	Placebo + Placebo	27
Overall Study	COMPLETED	Nicotinamide Riboside + Resveratrol	33
Overall Study	COMPLETED	Nicotinamide Riboside + Placebo	28
Overall Study	COMPLETED	Placebo + Placebo	29
Overall Study	NOT COMPLETED	Nicotinamide Riboside + Resveratrol	0
Overall Study	NOT COMPLETED	Nicotinamide Riboside + Placebo	0
Overall Study	NOT COMPLETED	Placebo + Placebo	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03743636/flow